MyFinsight

HomeBlogAbout

MyFinsight

Making company financials insightful for everyone

  • About
  • Blog
  • Privacy Policy
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

Cash Flow Overview

Free Cash flow
-$9,424K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
    • Maturities of available-for-sale...
    • Amortization of right-of-use ass...
    • Depreciation and amortization
    • Others
Negative Cash Flow Breakdown
    • Purchases of available-for-sale ...
    • Accounts payable and accrued exp...
    • Operating lease liability
    • Others
Cash Flow
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Consolidated net loss
-10,310
-10,792
-13,964
-25,746
Depreciation and amortization
168
162
166
165
Stock-based compensation
1,145
1,307
1,207
1,307
Accretion of discount of available-for-sale investment securities
146
255
361
512
Amortization of right-of-use assets
237
232
228
224
Gain on disposal of property and equipment
-
-
12
-
Gain on financing lease bargain purchase option
48
-
-
-
Other receivables
-59
-396
-169
544
Prepaid expenses and other assets
-18
-91
-1,094
-4,795
Accounts payable and accrued expenses
-266
-3,467
-536
18
Operating lease liability
-208
-191
-187
-183
Net cash used in operating activities
-9,351
-12,517
-12,196
-20,476
Purchases of property and equipment
73
138
31
37
Purchases of available-for-sale investment securities
7,978
5,868
12,845
39,340
Maturities of available-for-sale investment securities
23,373
17,500
29,307
19,000
Proceeds from sale of property and equipment
-
-
12
-
Net cash provided by (used in) investing activities
15,322
11,494
16,443
-20,377
Proceeds from issuance of common stock through option exercises
0
0
0
0
Proceeds from issuance of common stock through employee stock purchase plan
16
-
29
0
Proceeds from issuance of common stock from at-the-market offerings, net of offering costs
0
0
-21
29,753
Proceeds from issuance of common stock from underwritten follow-on public offering, net of offering costs
-
-
0
-
Principal paid on finance lease liabilities
145
142
139
136
Net cash (used in) provided by financing activities
-129
-142
-131
29,617
Net change in cash, cash equivalents and restricted cash
5,842
-1,165
4,116
-11,236
Cash, cash equivalents and restricted cash at beginning of period
11,813
12,978
8,862
14,006
Cash, cash equivalents and restricted cash at the end of period
17,655
-
-
-
Cash and cash equivalents at the end of period
16,160
-
-
-
Restricted cash at the end of period
1,495
-
-
-
Cash, cash equivalents and restricted cash at the end of period
17,655
11,813
12,978
8,862
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.

Time Plot

Show the time plot by selecting a row from the table.

Cash Flow

Maturities ofavailable-for-sale investment...$23,373K (-41.79%↓ Y/Y)Net cash provided by(used in) investing...$15,322K (1469.26%↑ Y/Y)Canceled cashflow$8,051K Net change in cash,cash equivalents and...$5,842K (-4.10%↓ Y/Y)Canceled cashflow$9,480K Purchases ofavailable-for-sale investment...$7,978K (-80.66%↓ Y/Y)Purchases of property andequipment$73K (711.11%↑ Y/Y)Stock-based compensation$1,145K (-53.89%↓ Y/Y)Amortization of right-of-useassets$237K (-45.77%↓ Y/Y)Depreciation andamortization$168K (-49.55%↓ Y/Y)Other receivables-$59K (95.23%↑ Y/Y)Prepaid expenses andother assets-$18K (98.75%↑ Y/Y)Proceeds from issuance ofcommon stock through...$16K (-79.75%↓ Y/Y)Net cash used inoperating activities-$9,351K (68.10%↑ Y/Y)Net cash (used in)provided by financing...-$129K (-100.35%↓ Y/Y)Canceled cashflow$1,627K Canceled cashflow$16K Consolidated net loss-$10,310K (70.04%↑ Y/Y)Principal paid on financelease liabilities$145K (-45.08%↓ Y/Y)Accounts payable andaccrued expenses-$266K (-154.85%↓ Y/Y)Operating lease liability-$208K (39.00%↑ Y/Y)Accretion of discount ofavailable-for-sale investment...$146K (-85.12%↓ Y/Y)Gain on financinglease bargain...$48K

aTYR PHARMA INC (ATYR)

aTYR PHARMA INC (ATYR)